FDA WARNING_LETTER - benjaminmcevoy.com - May 12, 2020
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
On May 14, 2020, the FDA and FTC issued a Warning Letter to Benjamin McEvoy regarding unapproved and misbranded products related to COVID-19. The agencies reviewed www.benjaminmcevoy.com on May 6 and May 12, 2020, observing that the website participates in the Amazon Associates program, promoting dietary supplements with claims implying they can mitigate, prevent, treat, diagnose, or cure COVID-19.
These claims cause the Amazon associate products to be unapproved new drugs under section 505(a) of the FD&C Act (21 U.S.C. § 355(a)) and misbranded drugs under section 502 (21 U.S.C. § 352). Introducing or delivering these products into interstate commerce is prohibited under sections 301(a) and (d) (21 U.S.C. § 331(a) and (d)), and misbranding after shipment in interstate commerce is prohibited under section 301(k) (21 U.S.C. § 331(k)).
The letter cites examples of claims from https://benjaminmcevoy.com/top-7-supplements-boosting-immune-system/ that establish intended use for COVID-19. The FDA requests immediate cessation of promoting and participating
ID · f06a5845-5ab7-4b05-ade7-1c87a4bc9508
Full citation text and observation details available on the Dashboard.